CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies

References

• Kassianos AJ, Jongbloed SL, Hart DNJ, et al. Isolation of human blood DC subtypes. Methods Mol Biol. 2010;595:45–54.
   PubMedGoogle Scholar
• Autenrieth SE, Grimm S, Rittig SM, et al. Profiling of primary peripheral blood- and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 workshop in wollongong, Australia. Clin Transl Immunology. 2015;4(11):e50.
   PubMedGoogle Scholar
• Minami H, Nagaharu K, Nakamori Y, et al. CXCL12-CXCR4 axis is required for contact-mediated human B lymphoid and plasmacytoid dendritic cell differentiation but not T lymphoid generation. J Immunol. 2017;199(7):2343–2355.
   PubMed Web of Science ®Google Scholar
• Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3–20.
   PubMed Web of Science ®Google Scholar
• Chen M, McReynolds N, Campbell EC, et al. The use of wavelength modulated raman spectroscopy in label-free identification of T lymphocyte subsets, natural killer cells and dendritic cells. PLoS One. 2015;10(5):e0125158.
   PubMed Web of Science ®Google Scholar
• Ding Y, Ju X, Azlan M, et al. Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunol Lett. 2011;134(2):161–166.
   PubMed Web of Science ®Google Scholar
• Villani A-C, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335). doi:https://doi.org/10.1126/science.aah4573.
   PubMed Web of Science ®Google Scholar
• Leone DA, Kozakowski N, Kornauth C, et al. The phenotypic characterization of the human renal mononuclear phagocytes reveal a co-ordinated response to injury. PLoS One. 2016;11(3):e0151674.
   PubMed Web of Science ®Google Scholar
• Fournier N, Jacque E, Fontayne A, et al. Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern. MAbs. 2018;10(4):651–663.
   PubMed Web of Science ®Google Scholar
• Heidkamp GF, Sander J, Lehmann CHK, et al. Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Sci Immunol. 2016;1(6). doi:https://doi.org/10.1126/sciimmunol.aai7677.
   Google Scholar
• Tsoumakidou M, Kemp SJ, Thorley AJ, et al. Expression of blood dendritic cell antigens (BDCAs) by CD1a + human pulmonary cells. Respir Med. 2009;103(6):935–938.
   PubMed Web of Science ®Google Scholar
• Auray G, Keller I, Python S, et al. Characterization and transcriptomic analysis of porcine blood conventional and plasmacytoid dendritic cells reveals striking species-specific differences. J Immunol. 2016;197(12):4791–4806.
   PubMed Web of Science ®Google Scholar
• Riboldi E, Daniele R, Parola C, et al. Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. J Biol Chem. 2011;286(41):35329–35333.
   PubMed Web of Science ®Google Scholar
• Cao W, Bover L, Cho M, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med. 2009;206(7):1603–1614.
   PubMed Web of Science ®Google Scholar
• Talukder AH, Bao M, Kim TW, et al. Phospholipid scramblase 1 regulates toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Cell Res. 2012;22(7):1129–1139.
   PubMed Web of Science ®Google Scholar
• Röck J, Schneider E, Grün JR, et al. CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving syk, Slp65 and PLCgamma2. Eur J Immunol. 2007;37(12):3564–3575.
   PubMed Web of Science ®Google Scholar
• Yin Z, Dai J, Deng J, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189(6):2735–2745.
   PubMed Web of Science ®Google Scholar
• Finotti G, Tamassia N, Calzetti F, et al. Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells. J Leukoc Biol. 2016;99(1):107–119.
   PubMed Web of Science ®Google Scholar
• Brown FF, Campbell JP, Wadley AJ, et al. Acute aerobic exercise induces a preferential mobilisation of plasmacytoid dendritic cells into the peripheral blood in man. Physiol Behav. 2018;194:191–198.
   PubMed Web of Science ®Google Scholar
• Shirshev SV, Orlova EG, Loginova OA, et al. Hormonal regulation of dendritic cell differentiation in the thymus. Bull Exp Biol Med. 2018;165(2):230–234.
   PubMed Web of Science ®Google Scholar
• Jähn PS, Zänker KS, Schmitz J, et al. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. Cell Immunol. 2010;265(1):15–22.
   PubMed Web of Science ®Google Scholar
• Murray L, Xi Y, Upham JW. CLEC4C gene expression can be used to quantify circulating plasmacytoid dendritic cells. J Immunol Methods. 2019;464:126–130.
   PubMed Web of Science ®Google Scholar
• Chiffoleau E. C-Type Lectin-Like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front Immunol. 2018;9:227.
   PubMed Web of Science ®Google Scholar
• Jégouzo SAF, Feinberg H, Dungarwalla T, et al. A novel mechanism for binding of galactose-terminated glycans by the C-type carbohydrate recognition domain in blood dendritic cell antigen 2. J Biol Chem. 2015;290(27):16759–16771.
   PubMed Web of Science ®Google Scholar
• Jaehn PS, Zaenker KS, Schmitz J, et al. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38(7):1822–1832.
   PubMed Web of Science ®Google Scholar
• Aouar B, Kovarova D, Letard S, et al. Dual role of the tyrosine kinase syk in regulation of Toll-Like receptor signaling in plasmacytoid dendritic cells. PLoS One. 2016;11(6):e0156063.
   PubMed Web of Science ®Google Scholar
• Cao W, Rosen DB, Ito T, et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits toll-like receptor-induced interferon production. J Exp Med. 2006;203(6):1399–1405.
   PubMed Web of Science ®Google Scholar
• Cao W, Zhang L, Rosen DB, et al. BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol. 2007;5(10):e248.
   PubMed Web of Science ®Google Scholar
• Maridas DE, Hey-Cunningham AJ, Ng CHM, et al. Peripheral and endometrial dendritic cell populations during the normal cycle and in the presence of endometriosis. J Endometr Pelvic Pain Disord. 2014;6(2):67–119.
   PubMedGoogle Scholar
• Kirsche H, NiederfüHr A, Deutschle T, et al. Ratio of myeloid and plasmacytoid dendritic cells and TH2 skew in CRS with nasal polyps. Allergy. 2010;65(1):24–31.
   PubMed Web of Science ®Google Scholar
• Poposki JA, Peterson S, Welch K, et al. Elevated presence of myeloid dendritic cells in nasal polyps of patients with chronic rhinosinusitis. Clin Exp Allergy. 2015;45(2):384–393.
   PubMed Web of Science ®Google Scholar
• Spears M, McSharry C, Donnelly I, et al. Peripheral blood dendritic cell subtypes are significantly elevated in subjects with asthma. Clin Exp Allergy. 2011;41(5):665–672.
   PubMed Web of Science ®Google Scholar
• Rai V, Rao VH, Shao Z, et al. Dendritic cells expressing triggering receptor expressed on myeloid cells-1 correlate with plaque stability in symptomatic and asymptomatic patients with carotid Stenosis. PLoS One. 2016;11(5):e0154802.
   PubMed Web of Science ®Google Scholar
• Galgani M, Nugnes R, Bruzzese D, et al. Meta-immunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. Diabetes. 2013;62(7):2481–2491.
   PubMed Web of Science ®Google Scholar
• Pilichowska ME, Pinkus JL, Pinkus GS. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease): lesional cells exhibit an immature dendritic cell phenotype. Am J Clin Pathol. 2009;131(2):174–182.
   PubMed Web of Science ®Google Scholar
• Kishimoto K, Tate G, Kitamura T, et al. Cytologic features and frequency of plasmacytoid dendritic cells in the lymph nodes of patients with histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease). Diagn Cytopathol. 2010;38(7):521–526.
   PubMed Web of Science ®Google Scholar
• Morrison A, Macgregor I. Measurement of CD83 mRNA by real-time polymerase chain reaction to determine removal of dendritic cells by leucoreduction of whole blood. Transfus Med. 2007;17(3):175–181.
   PubMed Web of Science ®Google Scholar
• Rabelo M. D S, El-Awady A, Moura Foz A, et al. Influence of T2DM and prediabetes on blood DC subsets and function in subjects with periodontitis. Oral Dis. 2019;25(8):2020–2029.
   PubMed Web of Science ®Google Scholar
• Laban KG, Rijken R, Hiddingh S, et al. cDC2 and plasmacytoid dendritic cells diminish from tissues of patients with non-Hodgkin orbital lymphoma and idiopathic orbital inflammation. Eur J Immunol. 2020;50(4):548–557.
   PubMed Web of Science ®Google Scholar
• Galati D, Zanotta S, Polistina GE, et al. Circulating dendritic cells are severely decreased in idiopathic pulmonary fibrosis with a potential value for prognosis prediction. Clin Immunol. 2020;215:108454.
   PubMed Web of Science ®Google Scholar
• Reinartz SM, van Tongeren J, van Egmond D, et al. Dendritic cell subsets in oral mucosa of allergic and healthy Subjects. PLoS One. 2016;11(5):e0154409.
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Kludka-Sternik M, Kolarz B, et al. The expression of B7-H1 and B7-H4 co-stimulatory molecules on myeloid and plasmacytoid dendritic cells in pre-eclampsia and normal pregnancy. J Reprod Immunol. 2013;99(1–2):33–38.
   PubMed Web of Science ®Google Scholar
• Bos S, Poirier-Beaudouin B, Seffer V, et al. Zika virus inhibits IFN-α response by human plasmacytoid dendritic cells and induces NS1-dependent triggering of CD303 (BDCA-2) signaling. Front Immunol. 2020;11:582061.
   PubMed Web of Science ®Google Scholar
• Dhamanage A, Thakar M, Paranjape R. Human immunodeficiency virus-1 impairs IFN-Alpha production induced by TLR-7 agonist in plasmacytoid dendritic cells. Viral Immunol. 2017;30(1):28–34.
   PubMed Web of Science ®Google Scholar
• Gujer C, Murer A, Müller A, et al. Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 2019;3(7):1129–1144.
   PubMed Web of Science ®Google Scholar
• Boichuk SV, Khaiboullina SF, Ramazanov BR, et al. Gut-Associated plasmacytoid dendritic cells display an immature phenotype and upregulated granzyme B in subjects with HIV/AIDS. Front Immunol. 2015;6:485.
   PubMed Web of Science ®Google Scholar
• De Meirleir KL, Khaiboullina SF, Frémont M, et al. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins. In Vivo. 2013;27(2):177–187.
   PubMed Web of Science ®Google Scholar
• Pagliari C, Kanashiro-Galo L, Silva AA. D L, et al. Plasmacytoid dendritic cells in cutaneous lesions of patients with chromoblastomycosis, lacaziosis, and paracoccidioidomycosis: a comparative analysis. Med Mycol. 2014;52(4):397–402.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Vadakekolathu J, Watad A, et al. SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis Insights. Front Immunol. 2021;12:635018.
   PubMed Web of Science ®Google Scholar
• Sa Ribero M, Jouvenet N, Dreux M, et al. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737.
   PubMed Web of Science ®Google Scholar
• Nienhold R, Ciani Y, Koelzer VH, et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat Commun. 2020;11(1):5086.
   PubMed Web of Science ®Google Scholar
• Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910–941.
   PubMed Web of Science ®Google Scholar
• Gadanec LK, McSweeney KR, Qaradakhi T, et al. Can SARS-CoV-2 virus use multiple receptors to enter host cells? Int J Mol Sci. 2021;22(3):992.
   PubMed Web of Science ®Google Scholar
• Bond E, Liang F, Sandgren KJ, et al. Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations. J Invest Dermatol. 2012;132(1):114–123.
   PubMed Web of Science ®Google Scholar
• Kobie JJ, Treanor JJ, Ritchlin CT. Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody. Immunol Invest. 2014;43(6):606–615.
   PubMed Web of Science ®Google Scholar
• Liang F, Bond E, Sandgren KJ, et al. Dendritic cell recruitment in response to skin antigen tests in HIV-1-infected individuals correlates with the level of T-cell infiltration. AIDS. 2013;27(7):1071–1080.
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cao W, Liu Y-J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8(8):594–606.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Alm GV, Eloranta M-L. Type I interferon and lupus. Curr Opin Rheumatol. 2009;21(5):471–477.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA. 2006;103(8):2770–2775.
   PubMed Web of Science ®Google Scholar
• Abou Rahal J, Kurban M, Kibbi A-G, et al. Plasmacytoid dendritic cells in alopecia areata: missing link? J Eur Acad Dermatol Venereol. 2016;30(1):119–123.
   PubMed Web of Science ®Google Scholar
• Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407.
   PubMed Web of Science ®Google Scholar
• Huang K, Li Q-X, Bi F-F, et al. Comparative immunoprofiling of polymyositis and dermatomyositis muscles. Int J Clin Exp Pathol. 2018;11(8):3984–3993.
   PubMed Web of Science ®Google Scholar
• Lü J, Dai T, Li L, et al. Expression of retinoic acid-I nducible gene I in the muscle tissues of idiopathic inflammatory myopathies. Zhonghua Yi Xue Za Zhi. 2015;95(23):1823–1828. [].
   PubMedGoogle Scholar
• Lv J, Li L, Li W, et al. Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis. J Neuroimmunol. 2018;319:142–148.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou Y, Hu Y, et al. [Myopathy associated with anti-signal recognition peptide antibodies: five case reports]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019;44(12):1430–1436.
   PubMedGoogle Scholar
• Gallego C, Vétillard M, Calmette J, et al. CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation. Blood. 2021;137(20):2770–2784.
   PubMedGoogle Scholar
• Cheng M, Gu X, Herrera GA. Dendritic cells in renal biopsies of patients with acute tubulointerstitial nephritis. Hum Pathol. 2016;54:113–120.
   PubMed Web of Science ®Google Scholar
• Wilde B, van Paassen P, Damoiseaux J, et al. Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2009;24(7):2151–2156.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Metzke D, Guckelberger O, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol. 2011;166(1):46–54.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nakamura H, Takatani A, et al. Activation of toll-like receptor 7 signaling in labial salivary glands of primary Sjögren’s syndrome patients. Clin Exp Immunol. 2019;196(1):39–51.
   PubMed Web of Science ®Google Scholar
• Clarke LE, Helm KF, Hennessy J, et al. Dermal dendritic cells in psoriasis, nummular dermatitis, and normal-appearing skin. J Am Acad Dermatol. 2012;66(1):98–105.
   PubMed Web of Science ®Google Scholar
• Bech R, Otkjaer K, Birkelund S, et al. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Exp Dermatol. 2014;23(5):349–352.
   PubMed Web of Science ®Google Scholar
• Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol. 2012;167(5):1170–1174.
   PubMed Web of Science ®Google Scholar
• Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain. 2013;136(Pt 4):1048–1066.
   PubMed Web of Science ®Google Scholar
• Mitosek-Szewczyk K, Tabarkiewicz J, Wilczynska B, et al. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. J Neurol Sci. 2013;332(1–2):35–40.
   PubMed Web of Science ®Google Scholar
• Kavousanaki M, Makrigiannakis A, Boumpas D, et al. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum. 2010;62(1):53–63.
   PubMedGoogle Scholar
• Miyashita A, Fukushima S, Makino T, et al. The proportion of lymphocytic inflammation with CD123-positive cells in lupus erythematous profundus predict a clinical response to treatment. Acta Derm Venereol. 2014;94(5):563–567.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–277.
   PubMed Web of Science ®Google Scholar
• Saito Y, Ohnishi K, Miyashita A, et al. Prognostic significance of CD169+ lymph node sinus macrophages in patients with malignant melanoma. Cancer Immunol Res. 2015;3(12):1356–1363.
   PubMed Web of Science ®Google Scholar
• Tabarkiewicz J, Rybojad P, Jablonka A, et al. CD1c + and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol Rep. 2008;19(1):237–243.
   PubMed Web of Science ®Google Scholar
• Gadalla R, Hassan H, Ibrahim SA, et al. Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis. Breast Cancer Res Treat. 2019;174(3):679–691.
   PubMed Web of Science ®Google Scholar
• Silva L-C, Fonseca F-P, Almeida O-P, et al. CD1a + and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2020;25(1):e49–e55.
   PubMed Web of Science ®Google Scholar
• Pellicioli ACA, Bingle L, Farthing P, et al. Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T-cell analysis. J Oral Pathol Med. 2017;46(10):928–933.
   PubMed Web of Science ®Google Scholar
• Sakurai D, Uchida R, Ihara F, et al. Immunosuppressive property of submandibular lymph nodes in patients with head and neck tumors: differential distribution of regulatory T cells. BMC Res Notes. 2018;11(1):479.
   PubMedGoogle Scholar
• Zekri A-RN, El Deeb S, Bahnassy AA, et al. Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. WJG. 2018;24(11):1228–1238.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology. 2008;48(1):157–168.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Agostinelli C, Picci P, et al. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget. 2017;8(67):111836–111846.
   PubMedGoogle Scholar
• Garcia JA, Mekhail T, Elson P, et al. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011;107(4):562–570.
   PubMed Web of Science ®Google Scholar
• Sponaas A-M, Moharrami NN, Feyzi E, et al. PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 Therapy. PLoS One. 2015;10(10):e0139867.
   PubMed Web of Science ®Google Scholar
• Riemann D, Schütte W, Turzer S, et al. High PD-L1/CD274 expression of monocytes and blood dendritic cells is a risk factor in lung cancer patients undergoing treatment with PD1 inhibitor therapy. Cancers (Basel). 2020;12(10). doi:https://doi.org/10.3390/cancers12102966.
   Google Scholar
• Ross RL, Corinaldesi C, Migneco G, et al. Targeting human plasmacytoid dendritic cells through BDCA2 prevents inflammation and fibrosis in xenotransplant mouse model of scleroderma. bioRxiv. 2020:2020.01.30.925073. doi:https://doi.org/10.1136/annrheumdis-2020-218439.
   Google Scholar
• Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015;7(4):464–476.
   PubMed Web of Science ®Google Scholar
• Gardet A, Pellerin A, McCarl C-A, et al. Effect of in vivo hydroxychloroquine and ex vivo anti-BDCA2 mAb treatment on pDC IFNα production from patients affected with cutaneous lupus Erythematosus. Front Immunol. 2019;10:275. https://www.frontiersin.org/article/10.3389/fimmu.2019.00275
   PubMed Web of Science ®Google Scholar
• Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–1371.
   PubMed Web of Science ®Google Scholar
• Janovec V, Aouar B, Font-Haro A, et al. The MEK1/2-ERK pathway inhibits type I IFN production in plasmacytoid dendritic Cells. Front Immunol. 2018;9:364.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hossain DMS, Nechaev S, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013;121(8):1304–1315.
   PubMed Web of Science ®Google Scholar
• Schwingshackl P, Obermoser G, Nguyen VA, et al. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and sézary syndrome. Acta Derm Venereol. 2012;92(3):269–275.
   PubMed Web of Science ®Google Scholar
• Pileri A, Agostinelli C, Sessa M, et al. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch. 2017;470(5):575–582.
   PubMed Web of Science ®Google Scholar
• Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36(9):1302–1316.
   PubMed Web of Science ®Google Scholar
• Federmann B, Metzler G, Bonzheim I, et al. [Differential diagnostic specific skin infiltrates in chronic myelomonocytic leukemia]. Pathologe. 2015;36(5):494–497.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309–323.
   PubMed Web of Science ®Google Scholar
• Ray A, Buon L, Song Y, et al. Interaction of plasmacytoid dendritic cells and myeloma cells trigger tumor promoting transcriptional changes in multiple myeloma cells. Blood. 2019;134(Supplement_1):510–510.
   Google Scholar
• Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975–2987.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chan A, Waarts MR, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137(10):1377–1391.
   PubMed Web of Science ®Google Scholar
• Vermi W, Facchetti F, Rosati S, et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol. 2004;28(5):585–595.
   PubMed Web of Science ®Google Scholar
• Feuillard J, Jacob M-C, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556–1563.
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–246.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Hebeda K, Kremer M, et al. Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol. 2017;96(5):765–777.
   PubMedGoogle Scholar
• Sapienza MR, Pileri A, Derenzini E, et al. Blastic plasmacytoid dendritic cell neoplasm: State of the art and prospects. Cancers (Basel). 2019;11(5). doi:https://doi.org/10.3390/cancers11050595.
   Google Scholar
• Boiocchi L, Lonardi S, Vermi W, et al. BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood. 2013;122(2):296–297.
   PubMed Web of Science ®Google Scholar
• Julia F, Dalle S, Duru G, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673–680.
   PubMed Web of Science ®Google Scholar
• Ohe R, Aung NY, Shiono Y, et al. Detection of minimal bone marrow involvement of blastic plasmacytoid dendritic cell neoplastic Cells - CD303 immunostaining as a diagnostic tool. J Clin Exp Hematop. 2018;58(1):1–9.
   PubMed Web of Science ®Google Scholar
• Zalmaï L, Viailly P-J, Biichle S, et al. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. haematol. 2020. doi:https://doi.org/10.3324/haematol.2020.253740.
   Google Scholar
• Dargent J-L, Delannoy A, Pieron P, et al. Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol. 2011;38(11):893–898.
   PubMed Web of Science ®Google Scholar
• Pennisi M, Cesana C, Cittone MG, et al. A case of blastic plasmacytoid dendritic cell neoplasm extensively studied by flow cytometry and immunohistochemistry. Case Rep Hematol. 2017;2017:4984951.
   PubMed Web of Science ®Google Scholar
• Sumarriva Lezama L, Chisholm KM, Carneal E, et al. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality. Histopathology. 2018;73(5):767–776.
   PubMed Web of Science ®Google Scholar
• Tsagarakis NJ, Paterakis G. Dendritic cell leukemia: a Review. Curr Oncol Rep. 2020;22(6):55
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188–202.
   PubMed Web of Science ®Google Scholar
• Deconinck E, Petrella T, Garnache Ottou F. Blastic plasmacytoid dendritic cell neoplasm: clinical presentation and diagnosis. Hematol Oncol Clin North Am. 2020;34(3):491–500.
   PubMed Web of Science ®Google Scholar
• Wang W, Khoury JD, Miranda RN, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. Published Online. 2020;106(4):1047–1055.
   Web of Science ®Google Scholar
• Togami K, Chung SS, Madan V, et al. Sex-biased ZRSR2; mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. bioRxiv. Published online January 1, 2020. 2020.10.29.360503.
   Google Scholar
• Beird HC, Khan M, Wang F, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9(12):99.
   PubMedGoogle Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer Discov. 2017;7(2):156–164.
   PubMed Web of Science ®Google Scholar
• Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid Dendritic-Cell neoplasm. N Engl J Med. 2018;379(15):1479–1481.
   PubMed Web of Science ®Google Scholar
• Grushchak S, Joy C, Gray A, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine (Baltimore). 2017;96(51):e9452.
   PubMed Web of Science ®Google Scholar
• Narli Ozdemir Z, Cengiz Seval G, Sahin U, et al. Blastic plasmacytoid dendritic cell neoplasm: Single center experience on a rare hematological malignancy. Indian J Hematol Blood Transfus. 2021;37(1):67–75.
   PubMed Web of Science ®Google Scholar
• Lane AA. Novel therapies for blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol Clin North Am. 2020;34(3):589–600.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Konopleva M, Lane AA. More on blastic plasmacytoid Dendritic-Cell neoplasms. N Engl J Med. 2019;380(7):696–696.
   Google Scholar
• Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(16):4020–4027.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N. Targeting the p-D-C: easy as C-D-1-2-3? Blood. 2021;137(10):1277–1278.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Martinelli G, Todisco E, et al. Clinical profile of IMGN632, a novel CD123-Targeting Antibody-Drug conjugate (ADC), in patients with relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2020;136(Supplement 1):11–13.
   PubMedGoogle Scholar
• Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34(12):3228–3241.
   PubMed Web of Science ®Google Scholar
• Xue T, Budde LE. Immunotherapies targeting CD123 for blastic plasmacytoid dendritic cell Neoplasm. Hematol Oncol Clin North Am. 2020;34(3):575–587.
   PubMed Web of Science ®Google Scholar
• Treilleux I, Blay J-Y, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466–7474.
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L’Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7(12):1339–1346.
   PubMed Web of Science ®Google Scholar
• Labidi-Galy SI, Treilleux I, Goddard-Leon S, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology. 2012;1(3):380–382.
   PubMed Web of Science ®Google Scholar